Analysis of whether larotinib (Vitaika) is a targeted drug and its principle of action

Larotrectinib (trade name Vitrakvi) is an oral small molecule targeted drug jointly developed by Bayer (Bayer) and Loxo Oncology. It is mainly used to treat patients with NTRK gene fusion-positive solid tumors, covering multiple tumor types in children and adults. Larotrectinib is one of the first approved "tissue-independent" targeted drugs in the world, that is, its indications are based on molecular markers rather than the organ of origin of the tumor, marking an important progress in precision medicine.

Larotinib is clearly a targeted therapy drug. Unlike traditional chemotherapy, targeted drugs act on tumor-specific molecules or signaling pathways, and larotrectinib specifically targets NTRK (Neurotrophic Tyrosine Receptor Kinase) fusion protein. This precise effect enables the drug to exert an inhibitory effect on tumor cells while causing less damage to normal cells and reducing toxic and side effects, reflecting the advantages of targeted drugs.

Larotrectinib binds to the tyrosine kinase domain of the NTRK fusion protein, inhibiting its autophosphorylation and activation of downstream signaling pathways, including MAPK/ERK and PI3K/AKT signaling pathways. NTRK Fusion proteins usually cause abnormal cell proliferation and tumor growth. After blocking this signal, larotrectinib can effectively inhibit tumor cell proliferation and induce apoptosis, and show a high objective response rate in clinical practice.

In multiple clinical trials, the objective response rate of larotrectinib in patients with NTRK fusion-positive solid tumors can reach 70%, and the efficacy is significant in both children and adults. Due to its strong targeting specificity and controllable side effects, larotrectinib provides new hope for patients who previously lacked effective treatment options. In the future, with the popularization of genetic testing, more cancer patients may benefit from this precision-targeted drug, and its research in combination therapy and drug resistance management is also constantly advancing.

Reference link:https://www.drugs.com